Leveraging Large Language Models to Extract Prognostic Pathology Features in Ewing Sarcoma.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: Current risk stratification for Ewing sarcoma relies heavily on clinical factors such as metastatic status, failing to capture histologic heterogeneity as a potential prognostic indicator. Although pathology reports contain rich biological data, this information remains locked in unstructured narrative text, limiting large-scale retrospective analyses. We aimed to validate the utility of Large Language Models (LLMs) for scalable data abstraction and to identify prognostic histologic features from a large multi-institutional cohort. METHODS: We conducted a retrospective cohort study using data from six Children's Oncology Group (COG) clinical trials. We utilized an LLM-based pipeline (OpenAI o3) to extract structured variables-including immunohistochemical (IHC) markers and CD99 staining patterns-from digitized, Optical Character Recognition (OCR)-processed pathology reports. Extraction accuracy was validated against a human-annotated ground truth (n=200) and cross-validated against senior experts (n=48). We assessed the association between extracted features and Overall Survival (OS) using Kaplan-Meier analysis and multivariable Cox proportional hazards regression, adjusting for metastatic status. FINDINGS: We analyzed 931 diagnostic pathology reports from 185 institutions spanning over 21-years. The LLM achieved a weighted average accuracy of 94% across 17 IHC markers; in a cross-validation subset, the LLM outperformed human annotators (weighted average accuracy over 15 IHC markers: LLM o3: 98.1%, a pediatric resident 91.4%, and a pediatric oncologist 95.9%). Survival analysis identified Neuron-Specific Enolase (NSE) and S100 as significant prognostic biomarkers. After adjusting for metastatic status, NSE positivity was associated with significantly inferior survival (HR 2.15, 95% CI 1.15-4.02, p=0.016); this risk was most pronounced in patients with non-metastatic disease (HR 5.64, p=0.0055). Conversely, S100 positivity was associated with improved survival (HR 0.58, 95% CI 0.34-1.00, p=0.046). INTERPRETATION: LLM-assisted extraction of pathology variables is highly accurate and scalable, capable of unlocking "dark data" from historical clinical trials. We identified NSE as a potent risk factor and S100 as a protective marker in Ewing sarcoma, particularly in localized disease. These findings suggest that AI-derived histologic data can refine risk stratification and, if validated, warrant inclusion in future prospective trials.